are attempting to address the various challenges created by the widespread implementation of these agents.Cyclin-dependent kinase (CDK) 4/6 inhibitors in combination with endocrine therapy have become the standard-of-care therapy for patients with advanced-stage hormone receptor-positive breast cancer. ...
Background Combining cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors with endocrine therapy is an effective strategy to improve progression-free survival in hormone receptor-positive (HR+), human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer. There is a lack of ...
多项临床试验在这一话题中展开探索:SOLAR-1、BYLieve、FAKTION和CapitELLA-291均显示,PI3K/AKT通路抑制剂是CDK4/6i耐药HR+晚期乳腺癌的重要治疗选择。MAINTAIN和post-MONARCH研究则表明,切换另一种CDK4/6i仍可带来疗效。ADC方面,DESTI...
近日,来自荷兰癌症研究所肿瘤内科的Gabe S. Sonke与SONIA研究团队共同在Nature期刊发表题为Early versus deferred use of CDK4/6 inhibitors in advanced breast cancer(CDK4/6抑制剂在晚期乳腺癌中的早期应用与延迟应用)的文章。作为...
UniProt Universal Protein Resource Keywords HR-positive breast cancer Immunotherapy CDK4/6 inhibitors Network pharmacology Molecular docking Tumour immune microenvironment 1. Introduction Breast cancer (BC), particularly the hormone receptor-positive (HR + ) subtype, remains the primary cause of cancer-rela...
细胞周期蛋白依赖性激酶4和6抑制剂(CDK4/6i)联合内分泌疗法或能改善雌激素受体阳性、HER2阴性的晚期乳腺癌患者的预后,同时其还能被早期作为一线疗法或推迟到二线治疗。 近日,一篇发表在国际杂志Nature上题为“Early versus deferred use of CDK4/6 inhibitors in advanced breast cancer”的研究报告中,来自荷兰癌症研...
Denise A. Yardley, MD, discusses the promise of CDK4/6 inhibitors in estrogen receptor–positive breast cancer, and the potential with immunotherapy agents. Denise Yardley, MD CDK4/6 inhibitors have recently taken the forefront of the landscape when it comes to hormone-positive breast cancer, ...
Hope S. Rugo, MD, discusses questions regarding CDK4/6 inhibitors and targeted therapies in HR-positive, HER2-negative advanced breast cancer. Hope S. Rugo, MD CDK4/6 inhibitors, currently recognized as the frontline standard of care for patie...
Treating cancer with selective CDK4/6 inhibitors. Nat Rev Clin Oncol. 2016 Jul;13(7):417-30. 2.Sara M Tolaney, Andrew M Wardley, Stefania Zambelli, et al. Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone ...
Expert nurse practitioner and physician associate faculty will discuss the latest advances and potential with the CDK4/6 inhibitors for HR-positive/HER2-negative breast cancer care.